Government Seeks Data on Rituxan Marketing
From Bloomberg News
Genentech Inc. said it received a request for information from the U.S. attorney’s office about its promotion of the cancer drug Rituxan.
Genentech of South San Francisco received the subpoena as part of a civil and criminal investigation by the U.S. attorney in Philadelphia, Genentech said. A Genentech spokeswoman declined to comment on the reasons for the investigation.
Genentech shares rose 83 cents to $53.99 on the New York Stock Exchange before the subpoena was disclosed.
